This trial aims to evaluate a radiation-based treatment in men with prostate cancer who are undergoing surgery for their cancer.
This trial is treating patients with PSMA-expressing high-risk localized or locoregional advanced prostate cancer (HRCaP).
This is a radiation therapy and surgical trial.
You may be able to join this trial if:
- Your cancer has not spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
Study of the Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Radionuclide Therapy Prior to Radical Prostatectomy in Men With High-risk Localised Prostate Cancer
Other Non-Commercial Sponsor
Peter MacCallum Cancer Centre
Eligible patients will receive one or two cycles of 177Lu-PSMA followed by surgery (prostatectomy).
Recruiting Hospitals Read More